Predictors of mortality in atypical antipsychotic-treated community-dwelling elderly patients with behavioural and psychological symptoms of dementia: A prospective population-based cohort study from Italy

European Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2014, Pages 187-195

  Rafaniello, Concetta ^a   Lombardo, Flavia ^b   Ferrajolo, Carmen ^a   Sportiello, Liberata ^a   Parretta, Elisabetta ^a   Formica, Ranieri ^a   Potenza, Simona ^c   Rinaldi, Barbara ^a   Irpino, Antonio ^a   Raschetti, Roberto ^b   Vanacore, Nicola ^b   Rossi, Francesco ^a   Capuano, Annalisa ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c ITALIAN MEDICINES AGENCY   (Italy)

Author keywords

Atypical antipsychotic medications; BPSD; Dementia; Mortality predictor factors

Indexed keywords

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DEMENTIA; FEMALE; HUMANS; INDEPENDENT LIVING; ITALY; MALE; PHARMACOVIGILANCE;

EID: 84895075496     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1588-3     Document Type: Review

References (42)

1. Lobo A, Launer LJ, Fratiglioni L et al (2000) Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S4-S9
2. Fratiglioni L, Launer LJ, Andersen K et al (2000) Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54:S10-S15
3. Madhusoodanan S, Shah P, Brenner R et al (2007) Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? CNS Drugs 21:101-115
4. Jeste DV, Blazer D, Casey D et al (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33:957-970
5. Banerjee S (2009) The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services. Available at: http://psychrights.org/research/digest/nlps/ BanerjeeReportOnGeriatricNeurolepticUse.pdf).
6. Trifirò G, Spina E, Gambassi G (2009) Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 59:1-12
7. Lee PE, Gill SS, Rochon P (2006) Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia. Neuropsychiatr Dis Treat 2:521-529
8. Federal Drug Administration (2005) Public Health Advisory: deaths with antipsychotics in elderly patients with behavioural disturbances. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm053171.htm
9. Federal Drug Administration (2008) FDA news, June 16, 2008 - FDA requests boxed warnings on older class of antipsychotic drugs. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm
10. European Medicines Agency (2008) Opinion of the committee for medicinal products for human use pursuant to article 5(3) of regulation (EC) no 726/2004, on conventional antipsychotics. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/Other/2010/01/WC500054056.pdf
11. Dorsey ER, Rabbani A, Gallagher SA et al (2010) Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 170:96-103
12. Kales HC, Zivin K, Kim HM, Valenstein M et al (2011) Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 68:190-197
13. Franchi C, Tettamanti M, Marengoni A et al (2012) Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian Medicines Agency. Results from the EPIFARM-Elderly Project. Eur Neuropsychopharmacol 22:569-577
14. Wang PS, Schneeweiss S, Avorn J et al (2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353:2335-2341
15. Schneeweiss S, Setoguchi S, Brookhart A et al (2007) Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 76:627-632
16. Setoguchi S, Wang PS, Alan Brookhart M et al (2008) Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 56:1644-1650
17. Kales HC, Valenstein M, Kim HM et al (2007) Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164:1568-1576
18. Liperoti R, Onder G, Landi F et al (2009) All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 70:1340-1347
19. Gill SS, Bronskill SE, Normand SL et al (2007) Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146:775-786
20. Musicco M, Palmer K, Russo A et al (2011) Association between prescription of conventional or atypical antipsychotic drugs and mortality in older persons with Alzheimer's disease. Dement Geriatr Cogn Disord 31:218-224
21. Rochon PA, Normand SL, Gomes T et al (2008) Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 168:1090-1096
22. Raivio MM, Laurila JV, Strandberg TE et al (2007) Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 15:416-424
23. Kales HC, Kim HM, Zivin K et al (2012) Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169:71-79
24. Rossom RC, Rector TS, Lederle FA et al (2010) Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia? J Am Geriatr Soc 58:1027-1034
25. Nonino F, De Girolamo G, Gamberini L et al (2006) Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study. Neurol Sci 27:375-380
26. Agenzia Italiana del Farmaco-AIFA (2005) Il trattamento farmacologico dei disturbi psicotici in pazienti affetti da demenza. Available at: http://www.agenziafarmaco.gov.it/it/content/antipsicotici Accessed 24 June 2013
27. Agenzia Italiana del Farmaco-AIFA (2009) Il trattamento farmacologico dei disturbi psicotici nei pazienti affetti da demenza - secondo aggiornamento. Available at: http://www.agenziafarmaco.gov.it/it/content/il-trattamento- farmacologico-dei-disturbi-psicotici-nei-pazienti-affetti-da-demenza-%E2%80%93- second
28. Agenzia Italiana del Farmaco-AIFA (2005) Il trattamento farmacologico dei disturbi psicotici in pazienti affetti da demenza [media release]. Available at: http://www.agenziafarmaco.gov.it/it/content/trattamento-farmacologico-dei- disturbi-psicotici-pazienti-affetti-da-demenza
29. Chiabrando G, Bianchi S, Poluzzi E et al (2010) Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara. Eur J Clin Pharmacol 66:661-669
30. Schneider LS, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943
31. Liperoti R, Pedone C, Corsonello A (2008) Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Curr Neuropharmacol 6:117-124
32. Rountree SD, Chan W, Pavlik VN et al (2012) Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther 4:16
33. Vilalta-Franch J, López-Pousa S, Calvó-Perxas L et al (2012) Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry. doi: 10.1016/j.jagp.2013.01.051
34. Lopez OL, Wisniewski SR, Becker JT et al (1999) Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol 56:1266-1272
35. Doody R, Pavlik V, Massman P et al (2005) Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. Dement Geriatr Cogn Disord 20:198-208
36. Vaughan CJ (2003) Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 91:23B-29B
37. Khan SA, Goyal C, Chandel N et al (2013) Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study. J Nat Sci Biol Med 4(1):191-196
38. Pariente A, Fourrier-Réglat A, Ducruet T et al (2012) Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 172(8):648-653, discussion 654-655
39. Franceschi A, Tuccori M, Bocci G et al (2004) Drug therapeutic failures in emergency department patients. A university hospital experience. Pharmacol Res 49:85-91
40. Capuano A, Irpino A, Gallo M et al (2009) Regional surveillance of emergency-department visits for outpatient adverse drug events. Eur J Clin Pharmacol 65:721-728
41. Ruggiero S, Rafaniello C, Bravaccio C et al (2012) Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol 22:415-422
42. Brodaty H, Draper BM, Low LF (2003) Behavioural and psychological symptoms of dementia: a seven-tiered model of service delivery. Med J Aust 178:231-234